Skip to main content

Table 2 SPHK1 and S1P inhibitors in clinical development as anti-cancer therapies

From: Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer

Agent

Mechanism

Stage of Clinical Development

References

Safingol

SPHK1 inhibitor

Demonstrated safety in combination with cisplatin in Phase I trial in solid tumours

[43, 46, 47]

Fingolimod

S1P receptor antagonist

Licenced for use in multiple sclerosis. No data on clinical use in cancer

[29, 30, 44]

(FTY720)

Sonepcizumab

Humanised S1P neutralising monoclonal antibody

Demonstrated safety in Phase I trial in solid tumours

[48, 49]

(LT1009)